Relmada Therapeutics 2022 Earnings Call REL-1017 Results

Relmada Therapeutics' Q4 2022 earnings presentation dated March 23, 2023, discussing full-year financial results and clinical trial data for REL-1017, an investigational depression treatment. The Reliance I trial showed REL-1017 achieved a clinically meaningful 2.3-point improvement in MADRS depression scores versus placebo at Day 28.